- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Hepatitis C Drugs on WHO's "Essential Medicines" List
The addition by the World Health Organization follows requests by consumer groups for the agency to widen its list to include some of the latest treatments carrying high price tags.
As the debate over the cost of prescription drugs accelerates, the World Health Organization has added several treatments for cancer and hepatitis C to its list of so-called essential medicines, which the agency believes should be made available at affordable prices.
The move comes amid growing friction between payers — both public and private – and the pharmaceutical industry over drug pricing. The addition by the WHO follows requests by consumer groups for the agency to widen its list to include some of the latest treatments carrying high price tags.
Among the drugs added to the list are three hepatitis C treatments — Sovaldi and Harvoni, which are sold by Gilead Sciences, and the Viekira Pak medication sold by AbbVie. These medicines helped spark widening concerns last year over affordability.
Complete article on The Wall Street Journal: http://on.wsj.com/1zL7Cvf
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
